Other: lengthening adalimumab dosing interval (DrugBank: Adalimumab)
16 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 0 |
37 | Generalised pustular psoriasis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
56 | Behcet disease | 0 |
84 | Sarcoidosis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 0 |
151 | Rasmussen encephalitis | 0 |
160 | Congenital ichthyosis | 0 |
164 | Oculocutaneous albinism | 0 |
222 | Primary nephrotic syndrome | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03172377 (ClinicalTrials.gov) | May 3, 2017 | 29/5/2017 | Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | Crohn Disease in Remission;Crohn Disease | Other: Lengthening adalimumab dosing interval | Radboud University | Erasmus Medical Center | Active, not recruiting | 18 Years | N/A | All | 174 | Phase 4 | Netherlands |